These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 27569556)

  • 1. Metastatic Melanoma: Insights Into the Evolution of the Treatments and Future Challenges.
    Millet A; Martin AR; Ronco C; Rocchi S; Benhida R
    Med Res Rev; 2017 Jan; 37(1):98-148. PubMed ID: 27569556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kinase inhibitors and immune check-point blockade for the treatment of metastatic melanoma and advanced cancer: synergistic or antagonistic?
    Luke JJ; Ott PA
    Expert Opin Pharmacother; 2013 Dec; 14(18):2457-62. PubMed ID: 24138302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond.
    Menzies AM; Long GV
    Eur J Cancer; 2013 Oct; 49(15):3229-41. PubMed ID: 23870385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current status and future directions of molecularly targeted therapies and immunotherapies for melanoma.
    Miller DM; Flaherty KT; Tsao H
    Semin Cutan Med Surg; 2014 Jun; 33(2):60-7. PubMed ID: 25085663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Melanoma Treatments: Advances and Mechanisms.
    Marzuka A; Huang L; Theodosakis N; Bosenberg M
    J Cell Physiol; 2015 Nov; 230(11):2626-33. PubMed ID: 25899612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma.
    Wang AX; Qi XY
    IUBMB Life; 2013 Sep; 65(9):748-58. PubMed ID: 23893853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Upcoming strategies for the treatment of metastatic melanoma.
    Spagnolo F; Queirolo P
    Arch Dermatol Res; 2012 Apr; 304(3):177-84. PubMed ID: 22350184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cutaneous Adverse Events of New Anti-melanoma Therapies: Classification and Management.
    Hwang SJ; Anforth R; Carlos G; Fernandez-Peñas P
    Actas Dermosifiliogr; 2017; 108(1):6-16. PubMed ID: 27642030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [What's new in skin cancers?].
    Jouary T
    Ann Dermatol Venereol; 2014 Dec; 141 Suppl 4():S630-42. PubMed ID: 25539755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic treatment for BRAF-mutant melanoma: where do we go next?
    Menzies AM; Long GV
    Lancet Oncol; 2014 Aug; 15(9):e371-81. PubMed ID: 25079100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Not Available].
    Mateus C; Libenciuc C; Robert C
    Bull Cancer; 2016 Jun; 103(6 Suppl 1):S4-S11. PubMed ID: 27494973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival of melanoma patients treated with targeted therapy and immunotherapy after systematic upfront control of brain metastases by radiosurgery.
    Gaudy-Marqueste C; Dussouil AS; Carron R; Troin L; Malissen N; Loundou A; Monestier S; Mallet S; Richard MA; Régis JM; Grob JJ
    Eur J Cancer; 2017 Oct; 84():44-54. PubMed ID: 28783540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes in Melanoma Patients Treated with BRAF/MEK-Directed Therapy or Immune Checkpoint Inhibition Stratified by Clinical Trial versus Standard of Care.
    Goldman C; Tchack J; Robinson EM; Han SW; Moran U; Polsky D; Berman RS; Shapiro RL; Ott PA; Osman I; Zhong H; Pavlick AC; Wilson MA
    Oncology; 2017; 93(3):164-176. PubMed ID: 28601879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune consequences of kinase inhibitors in development, undergoing clinical trials and in current use in melanoma treatment.
    Vella LJ; Andrews MC; Behren A; Cebon J; Woods K
    Expert Rev Clin Immunol; 2014 Aug; 10(8):1107-23. PubMed ID: 24939732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma.
    Fattore L; Malpicci D; Marra E; Belleudi F; Noto A; De Vitis C; Pisanu ME; Coluccia P; Camerlingo R; Roscilli G; Ribas A; Di Napoli A; Torrisi MR; Aurisicchio L; Ascierto PA; Mancini R; Ciliberto G
    Oncotarget; 2015 Sep; 6(28):24823-41. PubMed ID: 26208478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecularly targeted therapies for melanoma.
    Liu LS; Colegio OR
    Int J Dermatol; 2013 May; 52(5):523-30. PubMed ID: 23590367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted therapies for metastatic melanoma.
    Chandra S; Pavlick AC
    Dermatol Clin; 2012 Jul; 30(3):517-24. PubMed ID: 22800555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Melanoma: understanding relevant molecular pathways as well as available and emerging therapies.
    McKibbin T
    Am J Manag Care; 2015 Sep; 21(10 Suppl):S224-33. PubMed ID: 26619296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy in melanoma: Recent advances and future directions.
    Franklin C; Livingstone E; Roesch A; Schilling B; Schadendorf D
    Eur J Surg Oncol; 2017 Mar; 43(3):604-611. PubMed ID: 27769635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions.
    Ralli M; Botticelli A; Visconti IC; Angeletti D; Fiore M; Marchetti P; Lambiase A; de Vincentiis M; Greco A
    J Immunol Res; 2020; 2020():9235638. PubMed ID: 32671117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.